Skip to main content
. 2022 Aug 26;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900

Figure 2. Relative Risk of Severe COVID-19 After mRNA or Inactivated SARS-CoV-2 Vaccine Regardless of Vaccine Combinations.

Figure 2.

Error bars indicate 95% CIs; M, mRNA-1273 (Moderna); P, BNT162b2 (Pfizer-BioNTech); S, CoronaVac (Sinovac) or BBIBP-CorV (Sinopharm). Analysis of relative risk and severe COVID-19 infection in adults aged 30 years and older by vaccine type and number of doses. Color-coded dots represent vaccine type and combination. SSS data point represents time interval of 15 to 330 days (0.5 to 11 months) since last vaccine dose.